OneSkin has closed an oversubscribed Series A investment round, bringing total funding for the brand to $20 million and fueling a new phase of growth and innovation in skin health. WHO: Founded by four Brazilian PhD scientists in 2016, OneSkin has been a first-to-market category leader in science-led topical skin longevity treatments. The brand’s novel approach led to the patented peptide and core ingredient OS-01. It is the first peptide scientifically proven to reverse skin’s biological age by preventing the accumulation of senescent cells, a major driver of aging, leaving skin looking and acting younger and healthier.The brand’s breakthrough age-decelerating science is backed by clinical testing and published in multiple peer-reviewed journals. In addition to procuring thousands of testimonials since launching in 2021, OneSkin is the first company to replicate skin aging in the lab to validate the skin’s biological age reversal of its proprietary peptide OS-01 on the cellular level. WHY: Resources from funding will fuel accelerated research and novel formulas, delivering expanded longevity solutions and rewriting a new way forward for the anti-aging skincare industry. The funding will also power an increase in human capital focused on growth opportunities and new sales channels for the business, creating more accessible pathways for consumers to access OneSkin’s advanced technologies.